Andrew Ko, who led UCSF's trials of daraxonrasib based on discovery science, tells what to know about the medicine, the science behind it and what it means for patients. . On the heels of the drug's FDA approval, he
The Verdict
ClassificationLikely AI
ConfidenceHigh confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/5a8be563-69c2-4737-a11d-ea9f8938d241)